Shineco Subsidiary Receives Marketing Approval From China's Regulatory Body For Its Cardiac 5-Minute Test
Portfolio Pulse from Happy Mohamed
Shineco, Inc. (NASDAQ:SISI) announced that its subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., received marketing and distribution approval from China's National Medical Products Administration (NMPA) for its Cardiac 5-Minute Test. The test, which can detect three major cardiac markers in one test, is the first and only product on the market in China to complete the detection process for cardiac markers within 5 minutes. The approval is expected to support Biowin's business development efforts in the Point-of-Care Testing industry.
July 10, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shineco's subsidiary, Biowin, received approval for its Cardiac 5-Minute Test from China's NMPA. This approval is a significant milestone for the company and is expected to support its business development efforts in the Point-of-Care Testing industry.
The approval of the Cardiac 5-Minute Test by China's NMPA is a significant milestone for Shineco and its subsidiary, Biowin. This approval not only validates the company's product but also opens up a new market for it in China. This could potentially lead to increased revenues and profitability for Shineco in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100